Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;7(10):ofaa405.
doi: 10.1093/ofid/ofaa405. eCollection 2020 Oct.

The BAS2IC Score: A Useful Tool to Identify Patients at High Risk of Early Progression to Severe Coronavirus Disease 2019

Charlotte Kaeuffer  1   2 , Yvon Ruch  1   2 , Thibaut Fabacher  3   4 , Olivier Hinschberger  5 , Joy Mootien  6 , Magali Eyriey  7 , Valentin Greigert  8 ; COVID-19 Alsace Study Group; Nicolas Meyer  3   4 , Samira Fafi-Kremer  2   9 , Nicolas Lefebvre  1   2 , Yves Hansmann  1   2 , Martin Martinot  7 , François Danion  1   2
Collaborators, Affiliations

The BAS2IC Score: A Useful Tool to Identify Patients at High Risk of Early Progression to Severe Coronavirus Disease 2019

Charlotte Kaeuffer et al. Open Forum Infect Dis. .

Abstract

We developed a score, with easily accessible data (age, sex, body mass index, dyspnea, inflammatory parameters), to predict the risk of rapid progression to severe coronavirus disease 2019. Using a cutoff of >6 points, the negative predictive value was 87%.

Keywords: C-reactive protein; COVID-19; body mass index (BMI); prognostic score; risk factors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Performance of the BAS2IC score developed to identify patients with coronavirus disease 2019 at a high risk of developing severe disease. (A) Receiver-operating characteristics analysis of the derivation cohort. (B) Number and proportion of patients from the derivation and the validation cohorts with points assigned ≤6 (left graph) and >14 (right graph) according to the severity of the disease. AUC, area under the curve.
See this image and copyright information in PMC

References

    1. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 13 March 2020 Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re.... Accessed 2 June 2020.
    1. Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France. Science 2020; 369:208–11. - PMC - PubMed
    1. Kaeuffer C, Le Hyaric C, Fabacher T, et al. Clinical characteristics and risk factors associated with severe COVID-19 in Eastern France: prospective analysis of 1,045 cases. Euro Surveill : 2020. In press. - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med 2020. doi:10.1056/NEJMoa2007764 - DOI - PubMed
    1. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020. doi:10.1056/NEJMoa2021436 - DOI - PMC - PubMed